12:00 AM
 | 
Jul 16, 2001
 |  BioCentury  |  Finance

Analyst picks & changes

Idec Pharmaceuticals Corp. (IDPH), San Diego, Calif.

Business: Cancer, Autoimmune/Inflammation

Merrill Lynch analyst Eric Hecht lowered his 2001 and 2002 EPS estimates for IDPH to $0.65 and $0.95 from $0.70 to $1.02, respectively, after IDPH said that based on partner

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >